ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.

Go Deeper

AI Powered

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks (Updated January 2025)

Interactive Chart

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.

×